The US Food and Drug Administration (FDA) has granted clearance for Find Therapeutics’ investigational new drug (IND) application to commence a Phase I trial of FTX-101, aimed at treating chronic optic neuropathy (CON).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,